USA – Nexus Pharmaceuticals, a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has opened Project Tomorrow, the company’s new, state-of-the-art manufacturing facility.
The Wisconsin based facility will enable the company to expand its capability to deliver dependable, life-saving treatments to millions of patients in need.
“Today marks another milestone in our company’s continued mission to manufacture specialty and generic injectables right here in America,” said Mariam S. Darsot, CEO and president, Nexus Pharmaceuticals.
The Phase I investment of US$100 million supports a new, three-story manufacturing facility with cutting-edge technology, including an advanced isolator system and multiple lyophilization (freeze-drying) machines for maximum product protection and sterility.
Construction of the facility began in August 2019 and was completed in 2021, with commercial production expected to commence in 2022. The construction and design of the building features eco-friendly green equipment and processes.
The full, multi-phase project is expected to be completed in ten years, with an estimated total investment of US$250 million.
Earlier this year, Nexus announced that it was ready to serve and support any efforts to increase vaccine manufacturing as a result of the Covid-19 pandemic.
Due to the brand-new manufacturing capacity of the facility, Nexus would be able to maintain the production of existing products and simultaneously begin manufacturing vaccines, unlike other veteran drug manufacturers, which may have to sacrifice the production of one critical-need drug for another.
U.S. Representative Bryan Steil, said, “One lesson we have all learned in the last year is the importance of a domestic supply of pharmaceuticals and other critical health care products. This new facility represents an incredible investment not just in Wisconsin, but in Nexus’ commitment to providing life-saving medicines manufactured right here in America.”
The facility is expected to bring over 77 new jobs in a variety of job functions in fields of high-tech manufacturing and science by 2022, creating more than 400 new local jobs long-term.
To meet these needs, Nexus plans to partner with local institutions to provide job training and career and research opportunities.
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE